Wall Street Sees 134% Upside for This Low-Float Biotech

Dear Reader,

While the biotech sector bounces between hype and hope, one under-the-radar NYSE AMEX name is quietly building what could be one of the most powerful drug delivery platforms we’ve seen in years.

Pull up SER.

This isn’t just another early-stage biotech. Serina Therapeutics (NYSEAMERICAN:SER) is a clinical-stage company with a next-generation drug delivery platform that could disrupt how some of the world’s most challenging diseases are treated. 

The float for Serina Therapeutics (NYSEAMERICAN:SER) is currently estimated at approximately 2.79 million shares, drawn from a total of 9.97 million shares outstanding.

Here’s why Serina Therapeutics could be on the verge of breaking out…

A Team That’s Done It Before

The founders of Serina Therapeutics aren’t newcomers. Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of PEGylated drugs at Shearwater Polymers, enabling over 30 FDA approvals and $140B+ in cumulative sales. 

Now they’re back with something even better: a next-gen polymer platform called POZ that is engineered to overcome the limitations of PEG and deliver powerful therapeutics with greater precision and safety.

Why This Setup Has Our Full Attention

1. Ultra Low Float: With just 2.79m shares in its float, SER is one of the tightest biotech setups we’ve seen. When the float is this small, even a little bit of buying pressure can send the price flying.

Low supply + real story = explosive potential.  

2. Major Pharma Partnership: They’ve already landed a non-exclusive license with Pfizer to use SER’s POZ polymers in LNP (lipid nanoparticle) delivery, one of biotech’s hottest arenas post-mRNA vaccine boom.

3. Next-Gen Delivery Tech: Serina’s POZ platform will enable controlled, once-weekly subcutaneous dosing for a wide range of drugs. It already has preclinical and early clinical validation and has the potential to revolutionize delivery across small molecules, RNA therapies, and ADCs.

4. Lead Drug Entering Trials in 2025: Their lead candidate, SER-252, is targeting advanced Parkinson’s Disease with a once-weekly POZ-apomorphine injection designed to eliminate motor complications without skin reactions. This is a huge market with unmet need, and trials are expected to begin next year.

5. Big-Name Backers: Serina Therapeutics’ largest shareholder is Juvenescence Ltd., who just closed a $150M Series B round led by Abu Dhabi-based health giant M42. The two are launching a drug development hub that could directly accelerate SER’s growth and clinical partnerships.

Serina Therapeutics is a stock most people haven’t heard of yet. But when you look closely, it has the makings of a quiet breakout story. 

Serina Therapeutics (NYSEAMERICAN:SER) is trading around $5.54 and hasn’t moved much lately, but sometimes, the quiet ones are the ones you need to watch. 

Right now, the chart shows something interesting. The short-term moving averages just crossed to the upside, which can be an early signal of strength. It’s been bouncing around the $5.45 support level and trying to push above $5.60. That zone has been tough to break, but each attempt is getting tighter and more controlled, almost like pressure building in a spring. 

Stocks that do this don’t stay quiet for long.

What’s happening underneath is the kind of setup that traders dream of. You’ve got a low-float stock sitting under key resistance levels, right when analyst attention is starting to pick up. 

Two Wall Street analysts currently have active Buy ratings on Serina Therapeutics (NYSE: SER), and they’re not shy about their targets.

Ram Selvaraju of H.C. Wainwright, a five-star rated analyst, initiated coverage on July 14, 2025, with a price target of $15, projecting a 170.83% upside from current levels. Meanwhile, Justin Walsh from JonesTrading reiterated his Buy rating on May 9, 2025, with an $11 price target, still implying nearly 99% upside.

That gives SER an average 12-month target of $13, representing a potential 134.72% gain over its current price of $5.54. The range between $11 and $15 suggests growing institutional confidence in the company’s long-term value — and with a float under 3 million shares, it won’t take much volume to push this stock higher if momentum kicks in.

If SER can close above $5.60 with conviction, we could see a quick move toward $6.20, maybe even $6.40 or more. And once that happens, the $7 range is back in play. For now, it’s quiet. But with this chart, this float, and the kind of sentiment starting to form around it, Serina Therapeutics looks like a powder keg waiting for a match.

Momentum is Building

Over the last six months, Serina Therapeutics (NYSEAMERICAN:SER) has:

• Raised $10M in capital for clinical trials

• Added heavy hitters to its Board

• Released a steady stream of updates and investor events

• Been featured in top-tier biotech investor webinars

Final Thoughts

This is the kind of biotech story that gets missed… until it doesn’t.

A low-float NYSEAMERICAN stock with tech validated by Pfizer, backers with deep pockets, and a leadership team with FDA drug success already on the scoreboard.

We’re officially kicking off coverage on Serina Therapeutics (NYSEAMERICAN:SER).

If this clears its recent highs with volume, this could get very interesting… very fast.

Stay tuned,

Kristen Harpula
Trading Whisperer, Editor